title: Comparative activity of carbapenem testing (the COMPACT study) in Turkey.
abstract: BACKGROUND
  Recent evidence indicates that Gram-negative bacterial pathogens, the most common of which are Pseudomonas spp., Enterobacteriaceae, and Acinetobacter baumannii, are frequent causes of hospital-acquired infections. This study aims to evaluate the in vitro activity of doripenem and comparator carbapenem antibiotics against Gram-negative clinical isolates collected from COMParative Activity of Carbapenem Testing (COMPACT) study centres in Turkey.
  
  
  METHODS
  Ten centres in Turkey were invited to submit Pseudomonas aeruginosa, Enterobacteriaceae, and other Gram-negative isolates from intensive care unit (ICU)/non-ICU patients with complicated intra-abdominal infections, bloodstream infections, or nosocomial pneumonia, including ventilator-associated pneumonia, between May and October 2008. Susceptibility was determined by each centre using E-test. A central laboratory performed species confirmation as well as limited susceptibility and quality-control testing.
  
  
  RESULTS
  Five hundred and ninety six isolates were collected. MIC90 values for doripenem, meropenem, and imipenem, respectively, were 32, ≥ 64, and ≥ 64 mg/L against Pseudomonas spp.; 0.12, 0.12, and 0.5 mg/L against Enterobacteriaceae; and ≥ 64 mg/L for each against other Gram-negative isolates. In determining the susceptibility of hospital isolates of selected Gram-negative pathogens to doripenem, imipenem, and meropenem, we found that against all pathogens combined, the MIC90 for ICU compared with non-ICU isolates was higher.
  
  
  CONCLUSIONS
  Doripenem showed similar or slightly better activity than meropenem and better activity than imipenem against the Gram-negative pathogens collected in Turkey.
authors.affiliation: Ondokuzmayis University, Kurupelit Kampüsü, Samsun, Turkey. hakanomu@omu.edu.tr
authors.forename: Hakan
authors.initials: H
authors.lastname: Leblebicioglu
authors.forename: Nedim
authors.initials: N
authors.lastname: Cakir
authors.forename: Mustafa
authors.initials: M
authors.lastname: Celen
authors.forename: Halil
authors.initials: H
authors.lastname: Kurt
authors.forename: Hakan
authors.initials: H
authors.lastname: Baris
authors.forename: Joerg
authors.initials: J
authors.lastname: Laeuffer
mesh_terms: D040981:Acinetobacter baumannii / Q000187:drug effects* / Q000302:isolation & purification; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015780:Carbapenems / Q000494:pharmacology*; D002648:Child; D002675:Child, Preschool; D003428:Cross Infection / Q000382:microbiology; D004755:Enterobacteriaceae / Q000187:drug effects* / Q000302:isolation & purification; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000382:microbiology*; D006761:Hospitals; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification; D014421:Turkey; D055815:Young Adult; D018440:beta-Lactam Resistance
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems